Form 4: Cyclo Therapeutics Director Markus Sieger Receives Stock Grant in Lieu of Cash Compensation

Director Markus Sieger of Cyclo Therapeutics, Inc. received 18,354 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024, in lieu of cash.

Summary

• Markus Sieger, a director of Cyclo Therapeutics, Inc., received 18,354 shares of common stock on August 16, 2024.
• The shares were granted as compensation for the second quarter of 2024, in lieu of cash, under the company's non-employee director compensation policy.
• The number of shares was calculated based on a closing price of $1.26 per share on August 16, 2024.
• Following the transaction, Sieger directly owns 347,100 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction of a director receiving stock compensation. The director taking stock instead of cash could be seen as a slightly positive sign.

Positives

• The director's decision to take stock in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Director compensation packages often include stock grants to align the interests of directors with those of shareholders. This is a common practice in publicly traded companies.

Comparison to Industry Standards

• Stock grants in lieu of cash are a fairly standard practice for compensating board members, particularly in smaller companies or those looking to conserve cash.
• The size of the grant (18,354 shares) would need to be compared to typical director compensation packages for similarly sized biotech companies to assess its relative value.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning their interests with those of other shareholders.

Key Dates